NCT03886077Completed
Study of Hepatitis Eradication Receiving Protease Inhibitor Administration
The Study of Hepatitis Eradication Receiving Protease Inhibitor Administration
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
This is a prospective, non-blinded cohort study that will assess the safety, tolerability, and antiviral efficacy of glecaprevir/pibrentasivir therapy given post-discharge to HCV-negative recipients of HCV infected donors. Patients who meet entry criteria will be enrolled while on the transplant waitlist. At the time of transplant, some donors will be HCV positive / NAT positive and some will not be infected. Enrolled patients who receive an HCV negative donor will serve as contemporaneous controls. All study subjects who receive an HCV positive organ will be confirmed to have acquired HCV infection and genotype will be assessed prior to treatment with therapy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 50 (actual)
- First submitted
- 20 Mar 2019
- Start date
- 20 Mar 2019
- Primary completion date
- 20 Dec 2024
- Lead sponsor
- Sentara Norfolk General Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT03886077
What you commit to
- Study type: Observational
- Participants enrolled: 50
- From 20 Mar 2019 to the primary completion date, 20 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Subjects who meet any of the following exclusion criteria cannot be enrolled in this study.
- Individuals under 18 years of age
- History of advanced liver disease, including active hepatitis B or C, detectable hepatitis B surface Ag, hepatitis B DNA, HCV RNA, or cirrhosis
- Pregnant individuals
- HIV antibody positive
Who the study is looking for
- Subjects must meet all of the inclusion criteria specified below in order to be eligible for participation in this study
- Willing and capable of providing written informed consent
- Age ≥18 years
- On UNOS list as a candidate for heart transplant
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sentara Norfolk General Hospital Coordinator of this site? Confirm its status | Norfolk | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.